



NZX/ASX Announcement

1 April 2026

Retirement of Director

Truscreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) wish to advise that Mr Christopher Horn has informed the Company of his intention to retire as a non-executive director following the filing of the Company's Preliminary Final results, expected to be on or around 31 May 2026.

Chris was appointed a non-executive director of TruScreen on 1 November 2013 and was part of the team instrumental in the Company's progression, including listing of the Company on the NZAX in November 2014, transition to the main board NZX in December 2018, and dual listing on the ASX in January 2021.

Chris has served the Company as an independent non-executive director, and Chairman of the Audit Committee. Chris was previously a senior partner of KPMG and brought to TruScreen, a wealth of business experience across various industries and geography. He made a significant contribution to the Company's financial reporting, corporate governance, and the ongoing commercial development of the TruScreen cervical cancer screening technology.

Executive Chairman Tony Ho said, *"Chris should be proud of his contribution, over 13 years, to be part of the commercialisation journey of TruScreen as a woman's health start up to where it is to-day, a leading global company recognized and endorsed by WHO as an important AI enabled cervical cancer technology that will assist WHO to achieve its 90-70-90 objectives towards eliminating cervical cancer. On behalf of the Board and management of the Company, I thank Chris for his significant contributions and counsel over many years. I understand that this is Chris' remaining professional engagement and wish Chris all the best in his retirement. No doubt his golf handicap will improve."*

On Chris's retirement, the Board will appoint Ms Christine Pears as Chair of the Audit Committee and will appoint a replacement Australian based Non-Executive Director in due course.

Authorised by the Board for filing with the NZX/ASX.

Anthony Ho
Executive Chairman



For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*



About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. DALTONbio's exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.